Worldwide, over 694 million people have been infected with SARS-CoV-2, with an estimated
55–60% of those infected developing COVID-19. Since the beginning of the pandemic in …

Numerous pathogens can infect the olfactory tract, yet the pandemic caused by SARS-CoV-
2 has strongly emphasized the importance of the olfactory mucosa as an immune barrier …

Abstract Coronavirus disease-2019 (COVID-19) is primarily a respiratory disease, however,
an increasing number of reports indicate that SARS-CoV-2 infection can also cause severe …

Vaccines against SARS-CoV-2 have been shown to be safe and effective but their protective
efficacy against infection in the brain is yet unclear. Here, in the susceptible transgenic K18 …

Pathology studies of SARS-CoV-2 Omicron variants of concern (VOC) are challenged by the
lack of pathogenic animal models. While Omicron BA. 1 and BA. 2 replicate in K18-hACE2 …

The olfactory mucosa is a component of the nasal airway that mediates the sense of smell.
Recent studies point to an important role for the olfactory mucosa as a barrier to both …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with
various neurological complications. Although the mechanism is not fully understood, several …

Summary COVID-19 convalescent plasmas (CCPs) are chosen for plasma therapy based on
neutralizing titers and anti-Spike immunoglobulin levels. However, CCP characteristics that …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continually evolving
resulting in variants with increased transmissibility, more severe disease, reduced …

Cancer resistance to immune checkpoint inhibitors motivated investigations into leveraging
the immunostimulatory properties of radiotherapy to overcome immune evasion and to …